CRDF
Price
$3.88
Change
+$0.26 (+7.18%)
Updated
Jun 6, 04:59 PM (EDT)
Capitalization
240.49M
55 days until earnings call
DBVT
Price
$9.05
Change
+$0.50 (+5.85%)
Updated
Jun 6, 04:59 PM (EDT)
Capitalization
217.64M
Interact to see
Advertisement

CRDF vs DBVT

Header iconCRDF vs DBVT Comparison
Open Charts CRDF vs DBVTBanner chart's image
Cardiff Oncology
Price$3.88
Change+$0.26 (+7.18%)
Volume$19.06K
Capitalization240.49M
DBV Technologies S.A
Price$9.05
Change+$0.50 (+5.85%)
Volume$100
Capitalization217.64M
CRDF vs DBVT Comparison Chart
Loading...
CRDF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DBVT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CRDF vs. DBVT commentary
Jun 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRDF is a Buy and DBVT is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 07, 2025
Stock price -- (CRDF: $3.62 vs. DBVT: $8.59)
Brand notoriety: CRDF and DBVT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRDF: 65% vs. DBVT: 34%
Market capitalization -- CRDF: $240.49M vs. DBVT: $217.64M
CRDF [@Biotechnology] is valued at $240.49M. DBVT’s [@Biotechnology] market capitalization is $217.64M. The market cap for tickers in the [@Biotechnology] industry ranges from $324.3B to $0. The average market capitalization across the [@Biotechnology] industry is $2.32B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRDF’s FA Score shows that 0 FA rating(s) are green whileDBVT’s FA Score has 0 green FA rating(s).

  • CRDF’s FA Score: 0 green, 5 red.
  • DBVT’s FA Score: 0 green, 5 red.
According to our system of comparison, both CRDF and DBVT are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRDF’s TA Score shows that 5 TA indicator(s) are bullish while DBVT’s TA Score has 4 bullish TA indicator(s).

  • CRDF’s TA Score: 5 bullish, 5 bearish.
  • DBVT’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, CRDF is a better buy in the short-term than DBVT.

Price Growth

CRDF (@Biotechnology) experienced а +8.23% price change this week, while DBVT (@Biotechnology) price change was -2.50% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +11.92%. For the same industry, the average monthly price growth was +17.56%, and the average quarterly price growth was +3.51%.

Reported Earning Dates

CRDF is expected to report earnings on Jul 31, 2025.

DBVT is expected to report earnings on Apr 11, 2025.

Industries' Descriptions

@Biotechnology (+11.92% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CRDF($240M) has a higher market cap than DBVT($218M). DBVT YTD gains are higher at: 177.994 vs. CRDF (-16.705). CRDF has higher annual earnings (EBITDA): -51.7M vs. DBVT (-107.89M). CRDF has more cash in the bank: 79.9M vs. DBVT (13M). CRDF has less debt than DBVT: CRDF (1.36M) vs DBVT (7.51M). CRDF has higher revenues than DBVT: CRDF (587K) vs DBVT (0).
CRDFDBVTCRDF / DBVT
Capitalization240M218M110%
EBITDA-51.7M-107.89M48%
Gain YTD-16.705177.994-9%
P/E RatioN/AN/A-
Revenue587K0-
Total Cash79.9M13M615%
Total Debt1.36M7.51M18%
FUNDAMENTALS RATINGS
CRDF vs DBVT: Fundamental Ratings
CRDF
DBVT
OUTLOOK RATING
1..100
2177
VALUATION
overvalued / fair valued / undervalued
1..100
68
Overvalued
91
Overvalued
PROFIT vs RISK RATING
1..100
88100
SMR RATING
1..100
9597
PRICE GROWTH RATING
1..100
3936
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
34n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CRDF's Valuation (68) in the null industry is in the same range as DBVT (91) in the Biotechnology industry. This means that CRDF’s stock grew similarly to DBVT’s over the last 12 months.

CRDF's Profit vs Risk Rating (88) in the null industry is in the same range as DBVT (100) in the Biotechnology industry. This means that CRDF’s stock grew similarly to DBVT’s over the last 12 months.

CRDF's SMR Rating (95) in the null industry is in the same range as DBVT (97) in the Biotechnology industry. This means that CRDF’s stock grew similarly to DBVT’s over the last 12 months.

DBVT's Price Growth Rating (36) in the Biotechnology industry is in the same range as CRDF (39) in the null industry. This means that DBVT’s stock grew similarly to CRDF’s over the last 12 months.

DBVT's P/E Growth Rating (100) in the Biotechnology industry is in the same range as CRDF (100) in the null industry. This means that DBVT’s stock grew similarly to CRDF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRDFDBVT
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
87%
Momentum
ODDS (%)
Bullish Trend 2 days ago
84%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
N/A
Bearish Trend 2 days ago
86%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
87%
Bearish Trend 2 days ago
89%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
88%
Advances
ODDS (%)
Bullish Trend 3 days ago
87%
Bullish Trend 2 days ago
79%
Declines
ODDS (%)
Bearish Trend 16 days ago
87%
Bearish Trend 5 days ago
89%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
87%
Aroon
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
84%
View a ticker or compare two or three
Interact to see
Advertisement
CRDF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DBVT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
OEPIX58.24N/A
N/A
Oil Equipment&Svcs UltraSector Pro Inv
PCHSX30.44N/A
N/A
Putnam Global Health Care C
HGORX57.68N/A
N/A
Hartford Growth Opportunities R3
SDVRX24.39N/A
N/A
PGIM Quant Solutions Mid-Cap Val R
FNIDX13.76N/A
N/A
Fidelity Intl Sustainability Idx

CRDF and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRDF has been loosely correlated with MRVI. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if CRDF jumps, then MRVI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRDF
1D Price
Change %
CRDF100%
-0.14%
MRVI - CRDF
43%
Loosely correlated
-1.81%
ABSI - CRDF
42%
Loosely correlated
-0.35%
NAMS - CRDF
40%
Loosely correlated
+0.67%
BEAM - CRDF
40%
Loosely correlated
-0.87%
ORMP - CRDF
39%
Loosely correlated
-5.70%
More

DBVT and

Correlation & Price change

A.I.dvisor tells us that DBVT and CRDF have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that DBVT and CRDF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DBVT
1D Price
Change %
DBVT100%
+5.53%
CRDF - DBVT
32%
Poorly correlated
-0.14%
SNPX - DBVT
29%
Poorly correlated
+3.19%
GLSI - DBVT
29%
Poorly correlated
+0.21%
LXRX - DBVT
26%
Poorly correlated
+8.86%
PASG - DBVT
26%
Poorly correlated
-6.83%
More